NeurologyLive® Mind Moments®

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this Mind Moments episode, Todd Arnedt, PhD, professor of psychiatry and neurology at Michigan Medicine-University of Michigan, joins the podcast to discuss the recently published American Academy of Sleep Medicine clinical practice guideline on combination treatment for chronic insomnia disorder in adults. Arnedt explains the rationale behind formal recommendations for concurrent use of cognitive behavioral therapy for insomnia (CBT-I) and pharmacotherapy, particularly as combination treatment becomes increasingly common in clinical practice. 
The conversation reviews the evidence supporting CBT-I as the preferred foundational treatment approach, where combination therapy may offer advantages over pharmacotherapy alone, and how clinicians should think about factors such as symptom burden, treatment goals, access to CBT-I, and patient preference when selecting treatment strategies. Arnedt also outlines ongoing research gaps involving sequential treatment approaches, medication classes, long-term outcomes, and personalized insomnia care. 
Looking for more Sleep Disorders discussion? Check out the NeurologyLive® Sleep Disorders clinical focus page.
Episode Breakdown:

1:15 – Why formal insomnia combination treatment guidance was needed

2:45 – Defining concurrent CBT-I and pharmacotherapy approaches

4:35 – Evidence supporting CBT-I as foundational insomnia treatment  

7:15 – Situations where combination therapy may improve patient outcomes

7:50 – Neurology News Network 

10:20 – Patient-specific factors influencing insomnia treatment selection

12:30 – Barriers involving CBT-I access, cost, and real-world implementation

16:55 – Research gaps surrounding sequencing, long-term outcomes, and personalization

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

Topline Phase 2 CELIA Results Show Diranersen Misses Primary End Point in Early Alzheimer Disease

FDA Grants Priority Review to Bayer’s Asundexian for Secondary Stroke Prevention

Dyne Submits BLA for Z-Rostudirsen in Exon 51 Skipping Duchenne Muscular Dystrophy

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this Mind Moments episode, Scott Grossman, MD, assistant professor of neurology and ophthalmology at NYU Grossman School of Medicine, discusses emerging research on inter-eye retinal nerve fiber layer (RNFL) asymmetry as a biomarker of prior optic neuritis in pediatric-onset multiple sclerosis (POMS). Drawing from data presented at the 2026 American Academy of Neurology Annual Meeting, Grossman explains how optical coherence tomography (OCT) may help improve diagnostic confidence in pediatric MS by identifying remote optic nerve injury, while also outlining how a 4-micron inter-eye RNFL difference emerged as the optimal threshold in this cohort. The conversation also explores the role of OCT within the updated 2024 McDonald Criteria, the feasibility of integrating OCT into routine neurology practice, challenges surrounding normative pediatric OCT data, and future research directions involving visible light OCT and broader population datasets. 
Looking for more Multiple Sclerosis discussion? Check out the NeurologyLive® Multiple Sclerosis clinical focus page.
Episode Breakdown:

1:15 – Optic nerve involvement and updated MS diagnostic criteria 

3:20 – Pediatric RNFL asymmetry thresholds and interpretation of study findings

5:15 – Clinical implications of OCT biomarkers in pediatric-onset MS 

6:40 – Neurology News Network 

8:40 – Feasibility of incorporating OCT into neurology and MS practice 

10:15 – Future research directions, including normative data and visible light OCT

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

FDA Approves AXS-05 as New Treatment for Alzheimer Disease Agitation

FDA Approves Ocrelizumab for Pediatric Patients With Relapsing-Remitting Multiple Sclerosis

Efgartigimod Gains FDA Approval as First Treatment for Seronegative Forms of Myasthenia Gravis

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this Mind Moments episode, Greg Pontone, MD, Chief of Aging Behavioral and Cognitive Neurology at the University of Florida, joins the podcast to discuss the interplay between cognition and Parkinson disease, with a focus on how clinicians can better recognize and manage cognitive changes across the disease course. Pontone outlines the prevalence of early cognitive impairment, noting that a significant proportion of patients may present with subtle deficits at diagnosis, particularly in executive function and processing speed. 
The conversation explores the impact of commonly used medications on cognition, including anticholinergics and benzodiazepines, and how clinicians can balance therapeutic benefit with cognitive risk. Pontone also reviews current treatment strategies, including cholinesterase inhibitors and memantine, while emphasizing the importance of nonpharmacologic approaches such as structured routines and cognitive training. Additional discussion highlights the evolving role of biomarkers, the overlap between Parkinson disease and Alzheimer pathology, and the need for earlier recognition, better patient education, and continued research to improve long-term cognitive outcomes in this population.
Looking for more Movement disorder discussion? Check out the NeurologyLive® Movement disorder clinical focus page.
Episode Breakdown:

1:10 – Prevalence and early signs of cognitive impairment in Parkinson disease 

2:30 – Medication-related cognitive effects and contributing drug classes

4:20 – Balancing therapeutic benefit vs cognitive risk in treatment decisions

6:05 – Current treatments for cognition, including pharmacologic and behavioral strategies

10:25 – Neurology News Network 

13:00 – Role of biomarkers and Alzheimer overlap in Parkinson cognition

15:45 – Future priorities for advancing cognitive care and research in PD

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

FDA Clears Cala kIQ Plus for Essential Tremor and Parkinson Disease Hand Tremor

FDA Issues Complete Response Letter for GTx-104 in Patients With Aneurysmal Subarachnoid Hemorrhage

Satralizumab Meets Primary End Point in Phase 3 METEOROID Study in MOGAD

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this Mind Moments episode, Julie Kurek, MD, Associate Professor of Neurology at Augusta University/Wellstar-MCG, joins the podcast to provide a clinical breakdown of how neurologists can differentiate dyskinesia from tremor in patients with Parkinson disease and other movement disorders. Drawing from bedside experience, Kurek outlines the key phenomenologic differences between these movements, emphasizing the importance of rhythm, distribution, and overall movement quality in distinguishing the two. 
The conversation also explores how timing in relation to levodopa dosing serves as a critical diagnostic anchor, including recognition of peak-dose and biphasic dyskinesias. Kurek discusses real-world challenges in identifying patient-specific patterns, the importance of clinician–patient communication, and common diagnostic pitfalls, particularly in younger-onset or atypical presentations. She also highlights the growing role of digital tools, including wearable sensors and adaptive deep brain stimulation, in improving longitudinal monitoring and refining diagnostic accuracy in movement disorders.
Looking for more Movement disorder discussion? Check out the NeurologyLive® Movement disorder clinical focus page.
Episode Breakdown:

1:10 – Clinical features distinguishing tremor vs dyskinesia at bedside 

3:50 – Role of medication timing and levodopa response patterns

9:00 – Identifying patient-specific patterns and symptom awareness challenges 

13:20 – Neurology News Network 

16:10 – Common diagnostic pitfalls in Parkinson disease and movement disorders

17:50 – Role of wearables, biomarkers, and adaptive DBS in differentiation

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

FDA Accepts Ultragenyx's Resubmitted BLA for MPS IIIA Gene Therapy UX111

Elecsys NfL Test Receives European Approval for Monitoring Neuroinflammation in Relapsing-Remitting Multiple Sclerosis

FDA Clears Cala kIQ Plus for Essential Tremor and Parkinson Disease Hand Tremor

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this Mind Moments episode, Sarah Hoffmann, MD, PhD, senior neurologist at Charité – University Medicine Berlin, provides clinical insight into the evolving and often challenging landscape of seronegative generalized myasthenia gravis (gMG). Drawing from both clinical experience and research, Hoffmann discusses how seronegative MG is defined in the absence of detectable antibodies and why it represents a heterogeneous and often underrecognized subgroup of patients. The conversation explores key diagnostic challenges, particularly in patients with limb-predominant symptoms, where differentiation from other neuromuscular or functional disorders can be difficult. Hoffmann also reviews current treatment approaches, noting that while standard therapies mirror antibody-positive MG, access to targeted treatments remains limited. Additional discussion focuses on the barriers to advancing clinical trials in this population, the need for reliable biomarkers to better stratify patients, and the importance of continually reassessing diagnosis in nonresponders to avoid both undertreatment and overtreatment.
Looking for more neuromuscular discussion? Check out the NeurologyLive® Neuromuscular clinical focus page.
Episode Breakdown:

1:15 – Defining seronegative MG and estimating prevalence within overall patient population 

2:15 – Diagnostic challenges and distinguishing seronegative MG from mimics and functional disorders 

5:35 – Role and limitations of antibody testing, electrophysiology, and pharmacologic response 

6:50 – Neurology News Network 

9:05 – Current treatment strategies and variability in access to targeted therapies 

11:55 – Barriers to clinical trials and need for improved patient stratification methods 

13:05 – Key unanswered questions including biomarkers and reassessing diagnosis in nonresponders 

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

FDA Accepts Zilganersen New Drug Application for Priority Review in Alexander Disease

FDA Grants Accelerated Approval to Tividenofusp Alfa for Neurologic Hunter Syndrome

FDA Approves Higher Strength, More Effective Nusinersen Dose for Spinal Muscular Atrophy

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.